KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Other Non-Current Liabilities (2016 - 2025)

Rigel Pharmaceuticals has reported Other Non-Current Liabilities over the past 16 years, most recently at $5.0 million for Q1 2025.

  • For Q1 2025, Other Non-Current Liabilities fell 87.49% year-over-year to $5.0 million; the TTM value through Mar 2025 reached $5.0 million, down 87.49%, while the annual FY2024 figure was $5.0 million, 87.48% down from the prior year.
  • Other Non-Current Liabilities for Q1 2025 was $5.0 million at Rigel Pharmaceuticals, roughly flat from $5.0 million in the prior quarter.
  • Over five years, Other Non-Current Liabilities peaked at $57.5 million in Q1 2021 and troughed at $5.0 million in Q4 2024.
  • A 5-year average of $40.9 million and a median of $42.1 million in 2023 define the central range for Other Non-Current Liabilities.
  • Biggest five-year swings in Other Non-Current Liabilities: skyrocketed 1050.66% in 2021 and later plummeted 87.49% in 2025.
  • Year by year, Other Non-Current Liabilities stood at $52.7 million in 2021, then dropped by 19.84% to $42.3 million in 2022, then dropped by 5.49% to $39.9 million in 2023, then crashed by 87.48% to $5.0 million in 2024, then changed by 0.0% to $5.0 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for RIGL at $5.0 million in Q1 2025, $5.0 million in Q4 2024, and $40.0 million in Q3 2024.